# Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

> **NCT04695769** · PHASE4 · COMPLETED · sponsor: **Helwan University** · enrollment: 281 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin
- **DRUG:** Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]

## Key facts

- **NCT ID:** NCT04695769
- **Lead sponsor:** Helwan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-21
- **Primary completion:** 2021-10-21
- **Final completion:** 2021-10-21
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2022-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04695769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04695769, "Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04695769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*